Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | APAF1 | O14727 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20378348 | 0.85 | POLB (0.57) | POLBMEN1KMT2AALDH1A1GAA | |
| SCHEMBL31150294 | 0.82 | POLB (0.42) | POLBKMT2AALDH1A1GAAKDM4E | |
| SCHEMBL28015987 | 0.82 | POLB (0.54) | POLBMEN1KMT2AALDH1A1GAA | |
| SCHEMBL17731231 | 0.81 | POLB (0.41) | POLBMEN1KMT2AALDH1A1GAA | |
| SCHEMBL840431 | 0.81 | POLB (0.45) | POLBMEN1KMT2AALDH1A1GAA | |
| SCHEMBL19119188 | 0.81 | POLB (0.57) | POLBMEN1KMT2AALDH1A1GAA | |
| SCHEMBL19668771 | 0.81 | MAPK1 (0.48) | POLBMEN1KMT2AALDH1A1GAA | |
| SCHEMBL22979354 | 0.79 | PDE4D (0.55) | MEN1KMT2AALDH1A1GAAKDM4E | |
| SCHEMBL22979503 | 0.79 | KDM4E (0.64) | POLBALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL26054464 | 0.79 | POLB (0.41) | POLBALDH1A1GAAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-07 | — | — | US | disclosed |
| US-10344026-B2 | Compositions and methods of targeting mutant K-ras | NANTBIO, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180201610-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIO, INC. | 2018-07-19 | — | — | US | disclosed |
| US-9932340-B2 | Substituted indoles | ABBVIE INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170349589-A9 | Substituted Indoles | ABBVIE INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170174688-A1 | Substituted Indoles | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| CN-1058490-C | Tetrazolinone derivatives | BAYER AGROCHEM KK (JP) | 2000-11-15 | — | — | CN | disclosed |
| EP-0695748-B1 | Tetrazolinone herbicides | BAYER AGROCHEM KK (JP) | 1999-05-06 | — | — | EP | disclosed |
| US-5589439-A | HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1996-12-31 | — | — | US | disclosed |
| CN-1122333-A | Tetrazolinone derivatives | BAYER AGROCHEM KK (JP) | 1996-05-15 | — | — | CN | disclosed |
| EP-0695748-A1 | Tetrazolinone herbicides | NIHON BAYER AGROCHEM K.K. (JP) | 1996-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | POLB 4667/4885MEN1 633/4885KMT2A 1299/4885 |
| US-20170174688-A1 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | POLB 4550/4885MEN1 183/4885KMT2A 64/4885 |
| US-10344026-B2 | Compositions and methods of targeting mutant K-ras | KRAS, NRAS, HRAS | POLB 2312/4885MEN1 545/4885KMT2A 2128/4885 |
| US-20180201610-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | KRAS, NRAS, HRAS | POLB 2312/4885MEN1 545/4885KMT2A 2128/4885 |
| US-20170349589-A9 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | POLB 4550/4885MEN1 183/4885KMT2A 64/4885 |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | POLB 4667/4885MEN1 633/4885KMT2A 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.